SAN FRANCISCO (MarketWatch) -- Acusphere Inc. ACUS, shares tumbled 27% to $3.02 in Tuesday morning trade. The Watertown, Mass.-based pharmaceutical company said Imagify met the primary endpoints for ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Acusphere, Inc. (ACUS.PK), a specialty pharmaceutical company, today announced that it had reached an agreement with the U.S. Food & Drug Administration (FDA) ...

Acusphere, Inc. (ACUSD.PK) today announced that it has submitted the Marketing Authorisation Application (MAA) for its lead product candidate, Imagify™ (Perflubutane Polymer Microspheres) lyophilisate ...

NEW YORK, May 1 (Reuters) - Acusphere Inc.'s experimental imaging agent for measuring blood flow in the heart met or exceeded two of its three main goals in a clinical trial that will be used to seek ...

LEXINGTON, Mass.--(BUSINESS WIRE)-- Acusphere, Inc. (ACUSD.PK) today announced that it has submitted the Marketing Authorisation Application (MAA) for its lead product candidate, Imagify™ ...

Acusphere, Inc. (ACUS), a specialty pharmaceutical company, today announced that it had reached an agreement with the U.S. Food & Drug Administration regarding the design of a new Phase 3 study of the ...

SILVER SPRING, Md., Dec 10 (Reuters) - A U.S. Food and Drug Administration advisory panel rejected Acusphere Inc's imaging contrast agent on Wednesday, saying possible risks outweighed its potential ...

Acusphere Inc. announced the submission of a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for approval to market its lead product candidate, Imagify™ (Perflubutane Polymer ...

WATERTOWN, Mass., Dec 10, 2008 (BUSINESS WIRE) -- Acusphere, Inc. today announced that NASDAQ has halted trading in the Company's common stock today. The Cardio Renal Advisory Committee to the U.S.